Subject(s)
Aryl Hydrocarbon Hydroxylases/genetics , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/physiology , Mixed Function Oxygenases/genetics , Proton Pump Inhibitors , Tacrolimus/therapeutic use , 2-Pyridinylmethylsulfinylbenzimidazoles , Benzimidazoles/therapeutic use , Cytochrome P-450 CYP2C19 , Drug Interactions , Famotidine/therapeutic use , Female , Humans , Lansoprazole , Male , Middle Aged , Omeprazole/analogs & derivatives , Omeprazole/therapeutic use , RabeprazoleABSTRACT
To examine the effects of ascites on tacrolimus disposition, the authors measured tacrolimus concentration in blood and ascitic fluid from a patient with a living related liver transplant recipient who required removal of 500 to 2400 mL ascitic fluid daily. Tacrolimus levels in ascitic fluid ranged from 0.07 to 0.29 ng/mL and in whole blood from 7.5 to 20.3 ng/mL. The tacrolimus concentration in ascitic fluid positively correlated with that in whole blood ( r = 0.878, P <0.0001). Because the amounts of tacrolimus excreted into the ascitic fluid corresponded to only 0.01% to 0.09% of the dose administered, the authors concluded that the effects of ascites on tacrolimus disposition were negligible even though large amounts of ascitic fluid were drained regularly.
